The surveillance of Neisseria gonorrhoeae antimicrobial susceptibility in the EU/EEA is essential for detecting emerging and increasing antimicrobial resistance. Since 2009, this surveillance has been co-ordinated by the European Centre for Disease Prevention and Control (ECDC).
The European Centre for Disease Prevention and Control (ECDC) has published a report today highlighting the threat of increasing antimicrobial resistance (AMR) in Neisseria gonorrhoeae.
Due to the concerning rise in sexually transmitted infection (STIs) transmission across Europe, the European Centre for Disease Prevention and Control (ECDC) is urging everyone to keep informed and practice safer sex as they leave for holidays, festivals, and travel this summer season.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 25-31 May 2024 and includes updates on avian influenza, respiratory viruses, invasive meningococcal disease, mass gatherings for Hajj in Saudi Arabia, cholera, chikungunya, dengue, and poliomyelitis.
This framework describes the building blocks and actions that ECDC will use to support and EU/EEA countries and the European Commission to achieve the Sustainable Development Goal (SDG).
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 18-25 May 2024 and includes updates on respiratory virus epidemiology in the EU/EEA, influenza, avian influenza, and cholera.
The decline in the reported number of new transmissions of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections across European Union (EU) and European Economic Area (EEA) countries has continued.
In this report, we provide an overview of the data reported by countries in the EU and EEA in 2023 to describe progress towards the 2025 interim targets for hepatitis elimination as outlined in the WHO European Region Action Plan 2022–2030.
In 2022, 23 273 cases of hepatitis C were reported in 29 EU/EEA countries. Excluding countries that only reported acute cases, 23 249 cases were notified, corresponding to a crude rate of 6.2 cases per 100 000 population.